MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
34.87
+0.86
+2.53%
Closed 17:42 05/12 EDT
OPEN
33.80
PREV CLOSE
34.01
HIGH
35.08
LOW
33.01
VOLUME
471.28K
TURNOVER
0
52 WEEK HIGH
40.65
52 WEEK LOW
8.75
MARKET CAP
2.07B
P/E (TTM)
-17.3267
1D
5D
1M
3M
1Y
5Y
1D
Healthcare stocks with A+ momentum investors are watching
Seeking Alpha · 19h ago
Weekly Report: what happened at TYRA last week (0504-0508)?
Weekly Report · 2d ago
Tyra Biosciences to present at BofA Securities Health Care Conference
PUBT · 5d ago
Tyra Biosciences to Participate in Upcoming Investor Conferences
PR Newswire · 5d ago
How TYRA-300 Bladder Cancer Data and New Trial Partnership Will Impact Tyra Biosciences (TYRA) Investors
Simply Wall St · 05/06 02:30
Buy Rating on Tyra Biosciences Backed by Dabogratinib’s Potential to Redefine Intermediate-Risk Bladder Cancer Treatment Ahead of Key Phase II SURF302 Data
TipRanks · 05/04 11:15
Weekly Report: what happened at TYRA last week (0427-0501)?
Weekly Report · 05/04 10:07
Weekly Report: what happened at TYRA last week (0420-0424)?
Weekly Report · 04/27 10:10
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.